<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725214</url>
  </required_header>
  <id_info>
    <org_study_id>2020-780</org_study_id>
    <nct_id>NCT04725214</nct_id>
  </id_info>
  <brief_title>Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma</brief_title>
  <official_title>Anlotinib Combined With STUPP Protocol as First-line Regimen for MGMT Nonmethylated Glioblastoma: a Multicenter, Open-label, Single-arm, Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the efficacy and safety of Anlotinib in combination with&#xD;
      STUPP regimen for MGMT promoter nonmethylated glioblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For MGMT unmethylated glioblastoma patients undergoing STUPP regimen adjuvant therapy, during&#xD;
      adjuvant chemotherapy, concurrent with anti-angiogenesis targeted therapy(Anlotinib&#xD;
      capsule,d1-14).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Adjuvant therapy with Anlotinib and Temozolomide for MGMT nonmethylated glioblastoma after concurrent chemo-radiotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year OS</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 12 months</time_frame>
    <description>1-year overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from enrollment to progression or death (for any reason),assessed up to 24months</time_frame>
    <description>Progression-Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Adverse events are described in terms of CTC AE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Health-related quality of life are measured by the EORTC-QL30/BN20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive function</measure>
    <time_frame>from enrollment to death (for any reason).assessed up to 24 months</time_frame>
    <description>Neurocognitive function are measured by John-Hopkins adapted cognitive exam (ACE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">33</enrollment>
  <condition>MGMT-Unmethylated Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For MGMT unmethylated glioblastoma, during temozolomide adjuvant, concurrent with anti-angiogenesis targeted therapy(Anlotinib capsule,d1-14)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>Anlotinib With STUPP Regimen</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>temozolomide capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-70 years,&#xD;
&#xD;
          2. Histologically proven diagnosis of glioblastoma (WHO grade IV),&#xD;
&#xD;
          3. Have received standard STUPP treatment plan,&#xD;
&#xD;
          4. Gross resection or partial resection of the tumor (confirmed by MRI)&gt; 50%,&#xD;
&#xD;
          5. The pathological tissue specimens are detected as MGMT unmethylated,6.Karnofsky&#xD;
             performance status ≥ 60,&#xD;
&#xD;
          6. No previous radiotherapy, chemotherapy, immunotherapy or biotherapy 7.Adequate bone&#xD;
             marrow function: Hemoglobin ≥ 100g/L，Platelets ≥ 80×109/L，Absolute neutrophil count&#xD;
             (ANC) ≥ 1.5×109/L&#xD;
&#xD;
        8.Adequate renal function: Serum creatinine ≤ 1.25 x UNL (upper normal limit) or creatinine&#xD;
        clearance ≥ 60 ml/min 9.Adequate hepatic function: serum bilirubin ≤ 1.5 x UNL, AST and ALT&#xD;
        ≤ 2.5 x UNL，ALP≤5x UNL 10.For females of child-bearing potential, negative serum pregnancy&#xD;
        test within 14 days prior to registration. Women of childbearing potential and male&#xD;
        participants must practice adequate contraception during participation in the study and&#xD;
        within 8 weeks after the last administration of the drug 11.Able to provide written&#xD;
        informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrent or multiple malignant gliomas&#xD;
&#xD;
          2. Subtentorial glioblastoma or metastatic lesions outside the skull&#xD;
&#xD;
          3. Have received radiotherapy, chemotherapy or other anti-tumor drugs for the disease&#xD;
             before surgery&#xD;
&#xD;
          4. Previously received radiation therapy for the head and neck cancer&#xD;
&#xD;
          5. Have received any antibody treatment before&#xD;
&#xD;
          6. Contraindication of radiotherapy and chemotherapy defined as follows: Acute bacterial&#xD;
             or fungal infection，Unstable angina and/or congestive heart failure within the last 6&#xD;
             months，co-morbidity with immunosuppressive therapy&#xD;
&#xD;
          7. Evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
          8. Prior invasive malignancy (except for non-melanomatous skin cancer or carcinoma in&#xD;
             situ of cervix)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qichun Wei, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qichun wei, MD</last_name>
      <phone>086-0571-87783521</phone>
      <email>qichun_wei@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>yongjie shui, MM</last_name>
      <phone>086-0571-87783521</phone>
      <email>syjhz@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

